TendoNova, founded with the mission to revolutionize orthopedic care, focuses on providing innovative medical technology solutions for office-based procedures addressing tendon injuries and pain. The company's core product, the Ocelot™ Nano, is a microinvasive tool designed for safe and effective percutaneous tenotomy, aimed at treating tendinopathy by fragmenting and debriding soft tissue. TendoNova targets a significant market of individuals suffering from chronic tendon pain, including conditions affecting the rotator cuff, elbow epicondyles, patellar tendon, and Achilles tendon.
Notable figures associated with TendoNova include experienced medical professionals and investors specializing in healthcare innovation. The company has achieved significant milestones, including the successful development and deployment of the Ocelot™ Nano in clinical settings. TendoNova's impact is marked by its contribution to reducing the need for more invasive surgical procedures, thereby improving patient outcomes and accessibility to effective tendon care.
